Romosozumab + Teriparatide for Osteoporosis
(CAT Trial)
Trial Summary
What is the purpose of this trial?
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you have been using bone health treatments, you may not be eligible to participate.
What data supports the effectiveness of the drug combination Romosozumab and Teriparatide for osteoporosis?
Is the combination of Romosozumab and Teriparatide safe for treating osteoporosis?
How is the drug combination of Romosozumab and Teriparatide for osteoporosis different from other treatments?
Romosozumab and Teriparatide work together to both build new bone and increase bone density, which is different from many other osteoporosis treatments that primarily focus on slowing bone loss. This combination offers a dual approach by stimulating bone formation and reducing the risk of fractures.7891011
Research Team
Benjamin Leder, MD
Principal Investigator
MGH
Eligibility Criteria
This trial is for postmenopausal women aged 45 and older who have osteoporosis with a high risk of fractures. Participants should not have used bone health treatments significantly before, nor should they have other bone diseases, serious kidney or liver issues, heart/lung problems, psychiatric disorders, abnormal calcium levels, severe vitamin D deficiency, anemia or a history of cancer (except skin cancer). They also shouldn't abuse alcohol or substances.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either romosozumab or a combination of romosozumab and teriparatide for the treatment of postmenopausal osteoporosis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Romosozumab
- Teriparatide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator